A study carried out at the San Pedro University Hospital in La Rioja concludes that switching from the original adalimumab to the biosimilar represents significant economic savings without reducing the effectiveness in the disease process, which contributes to the efficiency and sustainability of the healthcare system. .
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
